USP17L4, which stands for Ubiquitin-Specific Peptidase 17-Like Family Member 4, is a member of the deubiquitinating enzyme (DUB) family. The USP17 family, to which USP17L4 belongs, is characterized by its ability to cleave ubiquitin moieties from ubiquitinated proteins. This enzymatic process is critical for maintaining the balance of protein ubiquitination, a post-translational modification that typically marks proteins for degradation by the proteasome.The USP17 gene family, including USP17L4, is located on human chromosome 4q13 and includes several homologous genes that appear to have arisen from gene duplication events. These genes encode cysteine proteases that share a common USP domain but differ in their specific substrate affinities and expression patterns. USP17L4, much like its family members, is believed to play a role in the regulation of cellular processes by rescuing proteins from degradation, thereby impacting signal transduction, cell cycle control, and apoptosis.
USP17L4's precise biological functions remain less characterized when compared to other DUBs; however, DUBs are generally implicated in various cellular pathways and have been associated with the pathophysiology of diseases such as cancer, neurodegeneration, and infections. The deubiquitinating activity of USP17L4 potentially regulates the stability and function of key regulatory proteins within these pathways.The expression of USP17L4 and its family members is often induced by cytokines, suggesting a potential role in immune responses. The reversible nature of ubiquitination, mediated by enzymes like USP17L4, allows for dynamic control over protein function and signaling pathways within the cell. By modulating the ubiquitination status of target proteins, USP17L4 can affect a variety of cellular outcomes, including proliferation, differentiation, and stress responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can indirectly affect USP17L4 by altering proteasome-mediated protein degradation pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, potentially impacting USP17L4 by modulating the degradation of ubiquitinated proteins. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates ubiquitin ligase activity, which could indirectly influence USP17L4's role in protein ubiquitination and degradation. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Similar to thalidomide, it affects ubiquitin ligase activity, potentially impacting USP17L4. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Affects ubiquitin ligase activity, and could indirectly influence USP17L4 functions. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
A USP14 inhibitor, which could indirectly affect USP17L4 by altering overall ubiquitin-dependent proteasomal degradation. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An inhibitor of ubiquitin-activating enzyme E1, potentially affecting USP17L4 by influencing ubiquitin conjugation. | ||||||
P22077 | 1247819-59-5 | sc-478536 | 10 mg | $165.00 | ||
A USP7 inhibitor, potentially affecting USP17L4 through interconnected pathways within the ubiquitin-proteasome system. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
Targets USP2, potentially affecting USP17L4 indirectly through alterations in ubiquitin-mediated proteasomal degradation. | ||||||
UCH-L1 Inhibitor Inhibitor | 668467-91-2 | sc-356182 | 10 mg | $204.00 | 1 | |
A USP14 inhibitor, which might impact USP17L4 activity by influencing ubiquitin-dependent proteolysis. | ||||||